Malathy Puthan Shekhar
Biography
Dr. Malathy Shekhar is a Professor (Research Educator), tenured in the Departments of Oncology and Pathology
Dr. Malathy Shekhar Ph.D., is a Professor (RE) with tenure in the Departments of Oncology and Pathology and is a Scientific Member of the Molecular Therapeutics Program of Karmanos Cancer Institute. My research is focused on understanding the molecular and cellular basis of breast cancer and melanoma development and progression, and the molecular underpinnings of endocrine and chemotherapy resistance. Notable accomplishments of our laboratory include development of the first 3D system for interrogating stromal/cancer cell interactions and their impact on endocrine response, and development of the first small molecule inhibitor to target Rad6, a critical enzyme regulating translesion DNA synthesis and DNA damage tolerance. She received two US patents for these discoveries. Dr. Shekhar's research has been funded by several extramural and intramural grants. She has published over 75 original papers, reviews, and seven book chapters. She has been invited to serve on several national and international grant review panels. She reviews manuscripts for several prestigious journals and is on the editorial board of five journals. She is the Director of Curriculum for the Cancer Biology Graduate Program and serves on several university committees.
Office Address
Karmanos Cancer Institute
Elliman Building, RM-1148
421 E. Canfield
Detroit, MI 48201
Education/Training
M.Sc. and M.Phil in Biochemistry, University of Madras, India
PhD in Biochemistry, Indian Institute of Science, India
Postdoctoral training: University of Kansas Medical Center, Kansas City, KS
Postdoctoral training: University of Missouri-Columbia, Columbia, MO
Office Phone
313-578-4326
Honors and Awards
Wayne State University School of Medicine Teaching Award, 2022
Publications
- Elayoubi J, Chi J, Mahmoud AA, Alloghbi A, Assad H, Shekhar M, Simon MS. A review of endocrine therapy in early-stage breast cancer: The Journey from Crudeness to Precision. Amer J Clin Oncol. Am J Clin Oncol; 46(5):225-230, 2023.
- Haynes BH, Cunningham K, Shekhar MP. RAD6B inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by enhancing mitotic spindle damage. BMC Cancer 22: Article #1073 (16 pages), 2022.
- Nangia-Makker P, Shekhar MP, Hogan V, Balan V, Raz A. MYH9 binds to dNTPs via deoxyribose moiety and plays an important role in DNA synthesis. Oncotarget 13:534-550, 2022.
- Uddin M-H, Zhou J-Y, Pimentel J, Patrick SM, Kim S, Shekhar MP, Wu GS. Proteomic analysis identifies p62/SQSTM1 as a critical player in PARP inhibitor resistance. Front Oncol 12:908603, 2022.
- Gajan A, Sarma A, Kim S, Gurdziel K, Wu GS, Shekhar MP. Adaptive olaparib resistance does not impact triple negative breast cancer cisplatin sensitivity. Front Oncol 11:694793, 2021.